Does Intensive Treatment Affect Quality of Life in High-Risk Myeloma? | RADAR Trial | IMS 2026

Karthik Ramasamy, MD, PhD, of Oxford University Hospitals discusses early quality-of-life results from the UK RADAR trial in double-hit, ultra-high-risk newly diagnosed myeloma at IMS 2026 in Glasgow. Transplant-eligible patients received intensive five-drug therapy, a transplant, consolidation and two-drug maintenance. Viewers will learn that symptoms and overall health improved within the first six months despite this intensive approach, while emotional health and worries about the future still need attention. These are early data.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

Timestamps:
0:00 Introduction: Dr. Karthik Ramasamy, Oxford University Hospitals
0:07 The RADAR Trial: Transplant-Eligible High-Risk Myeloma
0:40 The Intensive Five-Drug Treatment Program
0:55 The Key Question: Quality of Life on Intensive Therapy
1:31 Early Results: Symptoms and Overall Health Improve
1:59 Emotional Health and Worries About the Future
2:25 The Drugs Used at Each Stage